Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease

Frontiers in Oncology

C. Benedikt Westphalen¹  Stefanie Corradini²  Maximilian Niyazi²  Farkhad Manapov²  Matthias F. Froelich³  Marcus Unterrainer⁴  Johannes Rübenthaler⁴  Moritz Wildgruber⁴  Wolfgang G. Kunz⁴  Dirk Mehrens⁴  Jens Ricke⁴  Max Seidensticker⁴ 

[1] Department of Medicine III, University Hospital, LMU Munich, Munich, Germany;Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany;Department of Radiology and Nuclear Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim-University of Heidelberg, Mannheim, Germany;Department of Radiology, University Hospital, LMU Munich, Munich, Germany;

关键词: OMD;    cost-effectiveness (economics);    radiation therapy (radiotherapy);    cancer;    SABR;   

DOI  :  10.3389/fonc.2021.667993

来源: DOAJ

【 摘 要 】

BackgroundIn certain malignancies, patients with oligometastatic disease benefit from radical ablative or surgical treatment. The SABR-COMET trial demonstrated a survival benefit for oligometastatic patients randomized to local stereotactic ablative radiation (SABR) compared to patients receiving standard care (SC) alone. Our aim was to determine the cost-effectiveness of SABR.Materials and MethodsA decision model based on partitioned survival simulations estimated costs and quality-adjusted life years (QALY) associated with both strategies in a United States setting from a health care perspective. Analyses were performed over the trial duration of six years as well as a long-term horizon of 16 years. Model input parameters were based on the SABR-COMET trial data as well as best available and most recent data provided in the published literature. An annual discount of 3% for costs was implemented in the analysis. All costs were adjusted to 2019 US Dollars according to the United States Consumer Price Index. SABR costs were reported with an average of $11,700 per treatment. Deterministic and probabilistic sensitivity analyses were performed. Incremental costs, effectiveness, and cost-effectiveness ratios (ICER) were calculated. The willingness-to-pay (WTP) threshold was set to $100,000/QALY.ResultsBased on increased overall and progression-free survival, the SABR group showed 0.78 incremental QALYs over the trial duration and 1.34 incremental QALYs over the long-term analysis. Treatment with SABR led to a marginal increase in costs compared to SC alone (SABR: $304,656; SC: $303,523 for 6 years; ICER $1,446/QALY and SABR: $402,888; SC: $350,708 for long-term analysis; ICER $38,874/QALY). Therapy with SABR remained cost-effective until treatment costs of $88,969 over the trial duration (i.e. 7.6 times the average cost). Sensitivity analysis identified a strong model impact for ongoing annual costs of oligo- and polymetastatic disease states.ConclusionOur analysis suggests that local treatment with SABR adds QALYs for patients with certain oligometastatic cancers and represents an intermediate- and long-term cost-effective treatment strategy.

【 授权许可】

Unknown